Advantages of Whole-Genome Sequencing for Identification of Tumor Etiology and Clinically Actionable Genomic Aberrations: Lessons from the Australian Melanoma Genome Project

James S. Wilmott; Nicholas K. Hayward; Graham J. Mann; Richard A Scolyer

doi:10.2217/mmt-2017-0008

Shared by

Richard A Scolyer

Advantages of Whole-Genome Sequencing for Identification of Tumor Etiology and Clinically Actionable Genomic Aberrations: Lessons from the Australian Melanoma Genome Project

Editorial Material 2017 en

Authors

JW
James S. Wilmott
NH
Nicholas K. Hayward
GM
Graham J. Mann

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2020

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

Felicity Newell, James S. Wilmott, Peter A. Johansson, Kátia Nones, Venkateswar Addala, Pamela Mukhopadhyay, Natasa Broit, Carol M. Amato, Robert J. Van Gulick, Stephen H. Kazakoff, Ann‐Marie Patch, Lambros T. Koufariotis, Vanessa Lakis, Conrad Leonard, Scott Wood, Oliver Holmes, Qinying Xu, Karl D. Lewis, Theresa Medina, René González, Robyn P.M. Saw, Andrew J. Spillane, Jonathan R. Stretch, Robert V. Rawson, Peter M. Ferguson, Tristan J. Dodds, John F. Thompson, Georgina V. Long, Mitchell P. Levesque, William A. Robinson, John V. Pearson, Graham J. Mann, Richard A Scolyer, Nicola Waddell, Nicholas K. Hayward

Article2019

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

Russell J. Diefenbach, Jenny Lee, Dario Strbenac, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Andrew J. Spillane, Jonathan R. Stretch, Robyn P.M. Saw, John F. Thompson, Sydney Ch’ng, Richard A Scolyer, Richard Kefford, Helen Rizos

Article2025

241eP Whole genome and RNA sequencing for the selection of targeted therapy in advanced cancer patients

Ouissam Al Jarroudi, S. Boyault, Camille Léonce, Anthony Ferrari, A. Buisson, I. Ray-Coquard, T. Bachelot, Mehdi Brahmi, A. Dufresne, Clélia Coutzac, Anne Mc Leer, S. Lantuejoul, Christine Vinciguerra, Louis Larrouquère, Alain Bonneville, Nadège Corradini, Pierre Leblond, Olivier Trédan, Jean Yves Blay, Pierre Saintigny

Preprint2023

Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

Jordi Abril‐Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alexander Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, Montserrat Domingo-Sàbat, Laura Royo, Nicholas K. Akers, Catherine E. Willoughby, Judit Peix, Miguel Torres‐Martín, Marc Puigvehí, Stefano Cairo, Margaret Childs, Rudolf Maibach, Rita Alaggio, Piotr Czauderna, Bruce Morland,

Preprint2023

Advantages of Whole-Genome Sequencing for Identification of Tumor Etiology and Clinically Actionable Genomic Aberrations: Lessons from the Australian Melanoma Genome Project

Discussion(0)

Related publications

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

241eP Whole genome and RNA sequencing for the selection of targeted therapy in advanced cancer patients

Data from Identification of &lt;i&gt;IGF2&lt;/i&gt; as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

Data from Identification of &lt;i&gt;IGF2&lt;/i&gt; as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma